Koninklijke Philips N.V.

NYSE:PHG

Medical - Devices

Healthcare
$29.81 +2.17%

+$0.57 today

Market cap
$29.11B
Beta
0.93
P/E (TTM)
23.1
EPS (TTM)
$1.02
Dividend yield
3.62%
52W Low $22.20High $33.44

Volume 1.45M

Average 1.17M

PHG EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Koninklijke Philips N.V.NYSE: PHG

EBITDA · Q2 FY2026 · quarter ended Jun 2026

EBITDA grows, but more slowly than its trailing trend

Q2 FY2026 EBITDA of €1.02B rose 49.6% year over year, behind the +62.1% change in trailing-twelve-month EBITDA. Sequentially, it rose 90.0% from the prior quarter. Over 3 fiscal years it compounded at +184.2% a year.

Context

  • EBITDA amounted to 14.8% of revenue in FY2025, up 4.5 pp from a year earlier.
  • EBITDA increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 10 analysts of €3.59B (+36.0%) for the fiscal year ending Dec 2026, a slowdown from the +42.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
€1.02B+90.0% QoQ
Last fiscal yearDec 2025
€2.64B+42.7% YoY
LTMJun 2026
€3.05B+62.1% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+49.6%+28.7%-20.9 pp
1 year+42.7%+36.0%-6.8 pp
3-year CAGR+184.2%+12.5%-171.6 pp
5-year CAGR+9.4%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

EUR · from the income statement

Latest · FY2025
2.64B EUR
Year-over-year change
+42.7%
4-year CAGR
+7.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How PHG compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +62.1% is the 2nd highest of 10, against a peer median of +9.8%.
  • EBITDA amounts to 17.3% of revenue for PHG, versus a peer median of 21.7%.
PHG Competitors
EBITDA for PHG and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MDTMedtronic plcLTM Jul 2026$10.27B USD+9.8%+4.1%27.3%
ABTAbbott LaboratoriesLTM Sep 2026$9.71B USD-17.7%+0.1%20.1%
BSXBoston Scientific CorporationLTM Jun 2026$5.8B USD+23.2%+23.0%27.6%
GEHCGE HealthCare Technologies Inc.LTM Jun 2026$3.07B USD-19.7%+6.1%15.2%
PHGKoninklijke Philips N.V.LTM Jun 2026€3.05B EUR+62.1%+184.2%17.3%
RMDResMed Inc.LTM Jun 2026$2.17B USD+12.7%+16.5%38.3%
SNNSmith & Nephew plcFY2025$1.34B USD+0.1%+5.1%21.7%
LIVNLivaNova PLCLTM Sep 2026$211.36M USD+363.4%—14.0%
IRMDIRadimed CorporationLTM Mar 2026$32.23M USD+25.1%+22.2%37.4%
NPCENeuroPace, Inc.LTM Mar 2026-$13.84M USD+3.2%—13.9%
Peer median (excluding PHG) —+9.8%+6.1%21.7%

Competitors are the stored peer set for PHG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue17.16B17.83B18.17B18.02B17.83B
Cost of Revenue9.99B10.63B10.72B10.25B9.78B
Gross Profit7.17B7.19B7.45B7.77B8.06B
Gross Margin41.8%40.4%41.0%43.1%45.2%
Research & Development1.81B2.09B1.89B1.75B1.7B
Selling, General & Admin4.86B5.29B5.13B5.07B4.97B
Operating Expenses6.62B8.72B7.56B7.24B6.63B
Depreciation & Amortization1.32B1.6B1.26B1.39B1.13B
EBITDA2B115M1.04B1.85B2.64B
EBITDA Margin11.6%0.6%5.7%10.3%14.8%
Operating Income553M(1.53B)(115M)529M1.42B
Operating Margin3.2%-8.6%-0.6%2.9%8.0%
Interest Income18M25M46M79M108.54M
Interest Expense164M244M306M337M332.34M
Other Income / Expenses(44M)(202M)(412M)(406M)(242M)
Income Before Tax509M(1.73B)(527M)123M1.18B
Pre-Tax Margin3.0%-9.7%-2.9%0.7%6.6%
Income Tax Expense(103M)(113M)(73M)963M282M
Net Income3.32B(1.61B)(466M)(702M)895M
Net Margin19.3%-9.0%-2.6%-3.9%5.0%
EPS (Basic)0.67(1.68)(0.49)(0.75)0.95
EPS (Diluted)0.64(1.68)(0.49)(0.75)0.93
Weighted Avg Shares907.46M952.46M948.79M933.37M962.37M
Weighted Avg Shares (Diluted)950.28M952.46M948.79M933.37M962.5M

Koninklijke Philips N.V.

NYSE:PHG

Intrinsic Alpha fair value

Locked

Current Price

$29.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.